Does it make sense to treat children for conditions, such as high cholesterol, type 2 diabetes and hypertension, with drugs that have only been approved for adults? If the potential benefit to the child is outweighed by the risk of harm or adverse events, then it makes sense, experts say.
Does It Make Sense To Treat children for conditions, such as high cholesterol, type 2 diabetes and hypertension, with drugs that have only been approved for adults? If the potential benefit to the child is outweighed by the risk of harm or adverse events, then it makes sense, experts say.
"This determination would certainly have to be made on a case-by-case basis," says Mesfin Tegenu, president of PerformRx, a pharmacy benefits manager (PBM) located in Philadelphia.
According to a 2007 study conducted by IMS in 2007, more than 40% of children between the ages of six and 14 take prescription medications, including those for asthma, allergy, ADHD, type I diabetes and other conditions.
Lon Castle, MD, senior director, Department of Medical and Analytical Affairs for Medco, is more concerned about the growing trend toward adult diseases in children, than the use of medications to treat those conditions.
"Many drugs tested for adults are appropriate for children, so I don't think the health of children is jeopardized by these drugs," he says, "but I am concerned that our lifestyle is creating conditions children shouldn't face until at least their 40s. This extra need for healthcare will overburden our system."
"I don't like to see an increased need for intervention, but realize that there is an opportunity to change lifestyle behavior delaying or mitigating complications from obesity," he says. "On the other hand, I am concerned that medications will be used instead of diet and exercise."
According to Michael S. Jacobs, national clinical practice leader with Buck Consultants in Atlanta, treating children with drugs designed for adult diseases has the potential to send a message that unhealthy behavior is acceptable because the responsibility to treat the problem lies with other sources or the problem will be solved by science at the expense of employers or the government.
"The drugs have a tendency to work to resolve an immediate health condition," Jacobs continues, "but they do not work to solve the underlying problems-an unhealthy diet and lack of exercise. So lowering the cholesterol in a child, for example, is not the solution, but might buy time to get the child to solve the problem."
According the General Accountability Office (GAO) in a paper released in 2007, only about one-third of the drugs that are prescribed for children have been studied and labeled for pediatric use.
"The use of medications in the pediatric population that have been approved for use in adults for the treatment of 'adult diseases' has been a topic of controversy for decades," Tegenu says. "It has been a rather hot topic for the past 10 years with a significant number of legislative and FDA initiatives enacted to provide more information on the effects of these drugs in infants, adolescents, and teens."
One of the concerns is that medications prescribed for adults at certain dosages do not always translate to children, who are physiologically different.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More